Fleming Asset Management has introduced the Global Life Sciences Fund, which aims to entice sophisticated investors willing to add a high risk fund to their portfolios.
The fund is an offshore Oiec and invests in companies involved in the healthcare and medical research and development sector, such as genetic research and the pharmaceutical industry.
Biotechnology has become increasingly controversial in recent years due to the nature of some of the research being done, like cloning. Fleming feels that cloning research as well as future breakthroughs in studies of human DNA, which could lead to the development of new drugs and medical techniques, will benefit the fund.
However the ethics surrounding this research has made it a volatile area and this volatility may well increase in the future as the debate into genetic research continues.
According to Standard & Poor's Micropal the Fleming Select Global Bond is ranked 13 out of 33 funds, based on £1,000 invested on a bid-to-bid basis with net income reinvested over three years to May 1, 2000.